Seres Therapeutics (MCRB) Receivables (2016 - 2026)

Seres Therapeutics has disclosed Receivables across 9 years of filings, most recently posting $274000.0 for Q2 2026.

• In Q2 2026, Receivables changed N/A year-over-year to $274000.0; the TTM figure through Jun 2026 stood at $274000.0 (changed N/A YoY), while the FY2025 annual figure was $14.9 million, up 132.51% from the prior year.
• Receivables came in at $274000.0 for Q2 2026 at Seres Therapeutics, up from $233000.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $9.0 million in Q1 2025 to a low of $157000.0 in Q4 2025.
• Average Receivables over 3 years is $2.1 million, with a median of $339000.0 recorded in 2025.
• Year-over-year, Receivables plunged 94.15% in 2025 and slumped 97.42% in 2026.
• Over 3 years, Receivables stood at $2.7 million in 2024, then sank by 94.15% to $157000.0 in 2025, then surged by 74.52% to $274000.0 in 2026.
• Per Business Quant data, the three most recent Receivables figures were $274000.0 in Q2 2026, $233000.0 in Q1 2026, and $157000.0 in Q4 2025.